ProfileGDS5678 / 1417171_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 16% 16% 17% 79% 16% 15% 17% 17% 17% 16% 16% 20% 17% 16% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 12.4254816
GSM967853U87-EV human glioblastoma xenograft - Control 22.4013216
GSM967854U87-EV human glioblastoma xenograft - Control 32.4109417
GSM967855U87-EV human glioblastoma xenograft - Control 45.7086679
GSM967856U87-EV human glioblastoma xenograft - Control 52.3478516
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 12.433115
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 22.4402417
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 32.3936317
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 42.389917
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 12.3892516
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 22.3817316
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 32.4493420
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 42.4019517
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 52.3898416